New drug cocktail shows promise for tough stomach cancer
NCT ID NCT07334431
First seen Jan 12, 2026 · Last updated May 16, 2026 · Updated 18 times
Summary
This study is testing whether adding a drug called fruquintinib to standard chemotherapy and trastuzumab can help control advanced HER2-positive stomach or gastroesophageal junction cancer. It is for people who have not had prior treatment for their metastatic disease. The goal is to find the best dose and see if the combination slows cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital (Affiliated Cancer Hospital of Zhengzhou University)
RECRUITINGZhengzhou, Henan, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.